Leerink Partnrs Estimates XOMA’s Q1 Earnings (NASDAQ:XOMA)

XOMA Co. (NASDAQ:XOMA) – Stock analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for XOMA in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst D. Risinger expects that the biotechnology company will post earnings per share of ($0.31) for the quarter. The consensus estimate for XOMA’s current full-year earnings is ($1.41) per share. Leerink Partnrs also issued estimates for XOMA’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.00 EPS and FY2029 earnings at $8.86 EPS.

XOMA (NASDAQ:XOMA) last announced its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). The company had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.75 million. XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%.

Several other equities research analysts have also issued reports on XOMA. StockNews.com lowered shares of XOMA from a “hold” rating to a “sell” rating in a research note on Tuesday, February 25th. HC Wainwright dropped their price objective on XOMA from $123.00 to $104.00 and set a “buy” rating on the stock in a report on Monday, February 3rd.

XOMA Stock Performance

Shares of NASDAQ XOMA opened at $20.89 on Wednesday. The company has a market capitalization of $246.15 million, a PE ratio of -6.00 and a beta of 1.00. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The company’s fifty day moving average price is $24.64 and its 200 day moving average price is $27.29. XOMA has a 1 year low of $19.92 and a 1 year high of $35.00.

Institutional Investors Weigh In On XOMA

A number of large investors have recently modified their holdings of XOMA. Woodline Partners LP boosted its position in XOMA by 63.9% during the fourth quarter. Woodline Partners LP now owns 156,266 shares of the biotechnology company’s stock worth $4,107,000 after acquiring an additional 60,927 shares during the last quarter. Nuveen Asset Management LLC lifted its stake in XOMA by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company’s stock worth $377,000 after purchasing an additional 527 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of XOMA by 34.7% during the 4th quarter. Bank of America Corp DE now owns 7,796 shares of the biotechnology company’s stock worth $205,000 after purchasing an additional 2,009 shares during the last quarter. Northern Trust Corp grew its position in shares of XOMA by 1.5% in the fourth quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company’s stock valued at $2,396,000 after purchasing an additional 1,340 shares in the last quarter. Finally, Eversept Partners LP increased its holdings in shares of XOMA by 1.2% in the fourth quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company’s stock valued at $2,508,000 after purchasing an additional 1,128 shares during the last quarter. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Insider Buying and Selling

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the stock in a transaction on Friday, January 24th. The stock was sold at an average price of $26.10, for a total value of $13,069,366.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.20% of the company’s stock.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.